CA
NZ
UK
AU
IND
US
● CNS Pharmaceuticals fell about 8.9% after reporting second-quarter 2026 results showing a company in transition, with its lead brain-cancer program wound down.
● Benitec Biopharma fell about 8.5% in a recent session, a pullback that stands in contrast to the encouraging clinical narrative around gene therapy BB-301.
● Aardvark Therapeutics fell about 8.6% after confirming its lead program remains sidelined by a full FDA clinical hold.
● Silo Pharma fell roughly 13% ahead of its August 14, 2026 annual meeting, where shareholders will vote on a proposal to expand authorized common shares dramatically.
● Sutro Biopharma fell about 14.9% on August 12, 2026, even after reporting encouraging early clinical activity from next-generation candidate STRO-004.
● Obsidian Therapeutics fell roughly 15% in a volatile session shortly after itsNasdaqdebut, triggeringVolatilitytrading halts.
● PAVmed traded near $4.94 with a marketCapitalizationof roughly $36 million in early August, ahead of its August 14, 2026 second-quarterBusinessupdate.
● NeOnc Technologies fell about 20% to roughly $3.46 on August 12, 2026, even as the company reported positive topline Phase 2a results for lead brain-cancer candidate NEO100.
● Liquidia dropped despite Yutrepia net product sales of $170.4 million, up 31% sequentially, demonstrating a rapid launch trajectory in pulmonary arterial hypertension therapy.
● Minerva Neurosciences dropped as investors face a long wait for confirmatory Phase 3 data on roluperidone, a treatment for negative symptoms of schizophrenia.
Please wait processing your request...